Induced pluripotent stem cells (iPSCs) represent a groundbreaking advancement in biotechnology. iPSCs are a type of pluripotent stem cell generated by reprogramming adult somatic cells to an embryonic-like state, allowing them to differentiate into virtually any cell type in the body. This innovative technology provides a powerful tool for regenerative medicine, disease modeling, and drug discovery by offering a patient-specific source of cells for research and therapeutic applications. [Read more…]
Factor Bioscience and Eterna Therapeutics Forge Partnership to Fast-Track iMSC Therapies for Cancer, Autoimmune, and Rare Diseases
Factor and Eterna Announce Exclusive Collaboration Agreement to Accelerate iPSC-derived MSC Therapies for Oncology, Autoimmune, and Rare Diseases
CAMBRIDGE, Mass., Oct. 17, 2024 — Factor Bioscience Inc. and Eterna Therapeutics Inc. announced an exclusive license and collaboration agreement aimed at accelerating the development of advanced cell therapy candidates for oncology, rare diseases, and autoimmune disorders. Under the terms of the agreement, Eterna has secured a worldwide, exclusive, non-transferable, royalty-bearing license, with the right to grant sublicenses, to develop and market certain induced pluripotent stem cell (iPSC)-based cell therapy products (in particular iPSC derived mesenchymal stem cells (iMSC) that are engineered to express certain cytokines) utilizing Factor’s cell reprogramming and gene-editing technologies, patents, and know-how. The agreement positions both companies with the potential to accelerate the development of advanced cell therapies in the oncology, rare disease, and autoimmune fields. [Read more…]
HELP Therapeutics announces FDA clearance of IND application for universal iPSC-derived HiCM-188 cell therapy for the treatment of end-stage heart failure
NANJING, China, Oct. 22, 2024 — HELP Therapeutics Co. Ltd, a clinical-stage cell therapy company, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for “Allogeneic Human iPSC-derived cardiomyocytes (HiCM-188) administered via intramyocardial injection during coronary artery bypass graft surgery.” [Read more…]
Top 5 TED Talks About Stem Cells
Check out the best TED Talks below to understand the growing importance of stem cells within regenerative medicine.
In this article:
I Peace announces new iPSC lines to reduce immune rejection risk for U.S. population
More than 100 million people in the U.S. have this HLA-A haplotype
October 30, 2024, Palo Alto, CA –Â Leading G.M.P. cell CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the company has successfully generated iPS cell lines that are homozygous for HLA A, C, and DPA1. Two clonal lines are available for cell therapy developers and pharmaceutical companies as off-the-shelf products in both G.M.P. and research-grade. [Read more…]
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 79
- Next Page »